UK first in Europe to authorise orforglipron for weight management and type 2 diabetes
The MHRA authorised orforglipron (Foundayo) as a prescription-only GLP‑1 tablet in the UK for weight management and to improve glycaemic control in type 2…
Impact analysis · 50/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The MHRA authorised orforglipron (Foundayo) as a prescription-only GLP‑1 tablet in the UK for weight management and to improve glycaemic control in type 2 diabetes. The authorisation covers adults with obesity (BMI ≥30) or overweight (BMI 27–30 with comorbidity). The tablet is taken once daily with no food or water restrictions. The safety of orforglipron will remain under close MHRA review.
Quantitative evidence
- Authorisation granted on 10 August 2026
- Dosing escalation from 0.8 mg to 17.2 mg
- Pivotal trial data not cited in release
- Efficacy outcome specifics (weight loss %, A1C)
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Orforglipron is a novel oral non‑peptide small‑molecule GLP‑1 receptor agonist enabling weight loss and improved glycaemic control.
Market context
Eli Lilly gains a foothold in the UK obesity and type 2 diabetes market with an oral GLP‑1 option; NHS adoption remains uncertain.
Legal and regulatory context
This is an MHRA authorisation, enabling legal UK marketing; future NHS coverage depends on NICE assessment.
Related PharmaSignal profiles
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 362e51b90a2b3ef79adbd3e1c271d1ee5e6d3e9fb4efd3af9aa1e24534eec539
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-08-10T130913Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.